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ABSTRACT 
Aims: EGFR and ALK analysis is routinely undertaken prior to targeted treatment of 
non-squamous non-small cell lung carcinoma (NSCLC). Increasingly limited 
resources require molecular pathology services to be cost effective without detriment 
to patient care. 
 
Methods: Data from an audit of molecular pathology testing in the South East of 
Scotland Cancer network has been used to explore different testing strategies with the 
aim of reducing costs; including investigation of TTF1 expression as a negative 
predictor for EGFR mutations.  
 
Results: TTF1 immunohistochemistry had a high negative predictive value for EGFR 
mutations (99%). Reflex testing all non-squamous NSCLC had the highest costs 
whereas limiting testing to those who might be considered for treatment would save 
7.5%; a serial testing model could save 32.7%.  
 
Conclusions: Testing only patients being considered for EGFR and ALK inhibitors 
represented small savings; more significant savings would be achievable if testing 
algorithms utilized known associations between clinical biomarkers.  
 
INTRODUCTION 
Current UK and USA recommendations for the treatment of locally advanced or 
metastatic non-squamous non-small cell lung cancer (non-squamous NSCLC) include 
first line EGFR tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) for 
tumours with activating EGFR mutations; and ALK inhibitors (crizotinib and 
ceritinib) for patients whose tumours harbour ALK gene rearrangements.1-3 As a 
result, predictive EGFR mutation analysis has been carried out by clinical laboratories 
since 2009 and in 2013 ALK rearrangement analysis was added to the testing 
algorithm. Studies have shown that in a Caucasian population approximately 10% of 
NSCLC have EGFR mutations, 2 to 5% have ALK rearrangements, and 35% have 
KRAS mutations. Although there is no direct therapeutic value in the detection of 
somatic KRAS mutations it is performed in many laboratories as KRAS mutations are, 
in the vast majority of samples, mutually exclusive with EGFR and ALK mutations.4   
 
Thyroid transcription factor 1 (TTF1) has, for many years, been used as an 
immunohistochemical marker to aid the diagnosis of lung adenocarcinoma. 
Approximately 80% of non-squamous NSCLC requested for molecular pathology 
testing show positive nuclear staining with TTF1 antibodies.6 Several studies have 
shown a correlation between TTF1 protein expression and the presence of EGFR 
mutations (see table 1), indeed TTF1 IHC has been shown to be a good negative 
predictor of EGFR mutations in western populations; however, this association 
appears to be less strong in East Asian populations. 
Table 1: Studies comparing TTF1 IHC with the presence of EGFR mutations 
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Vallee et al. 6 1038 79.0% 3 98.6% France 
Vincenten et al. 7 797 67.9% 9 96.5% Netherlands 
Krawczyk et al. 8 727 80.4% 10 93.0% Poland 
Chatziandreou et al. 9 595 70.4% 2 98.9% Greece 
Sheffield et al. 10 306 77.1% 4 94.3% Canada 
Somaiah et al. 11  
(pilot and validation) 
301 90% 2 93.3% America 
131 72.5% 1 97.2% America 
Leary et al. 12 70 78.6% 0 100% Britain 
Zhang et al. 13 1042 87.2% 50 62.4% China 
Shanzhi et al. 14 660 98.5% 1 90% China 
Chung et al. 15 496 89.3% 17 67.92% Taiwan 
Sun et al. 16 190 79.5% 6 84.6% Korea 
Yatabe et al. 17 95 57.9% 7 82.5% Japan 
 
There is still debate as to the best approach for molecular pathology testing of lung 
cancers; some laboratories favour testing all patients with a histologically or 
cytologically diagnosed non-squamous non-small cell lung cancer, whereas others test 
only samples from patients being considered for EGFR or ALK targeted therapy. At 
present in the UK EGFR tyrosine kinase inhibitors are available as first line therapy to 
NHS patients with locally advanced or metastatic non-small cell lung cancer and 
EGFR activating mutations in their tumours. Crizotinib has only been recommended 
for previously treated patients with ALK-positive advanced NSCLC. Although a 
request based model may require rapid turnaround times in order to meet the clinical 
need it would be likely to reduce costs by avoiding testing unnecessary cases. This 
report explores options for improving cost efficiency in lung cancer molecular 
pathology without impacting patient care. 
 
METHODS 
 
The pathology laboratory based at the Royal Infirmary of Edinburgh provides 
molecular testing in lung cancer for the South East of Scotland cancer network 
covering NHS Lothian, NHS Borders, NHS Fife and NHS Dumfries and Galloway. A 
clinical audit was carried out of lung cancer Molecular Pathology requests across the 
network between January 2011 and March 2014. After histopathology assessment and 
macrodissection (as required) DNA was extracted from FFPE tissue using the 
QIAamp DNA FFPE tissue Kit (Qiagen). EGFR mutation analysis was carried out 
using the Therascreen EGFR RGQ PCR kit (Qiagen); mutations in KRAS codons 12, 
13 and 61 were detected using an in-house Pyrosequencing assay. Samples requiring 
ALK rearrangement analyses were initially screened for ALK protein expression by 
immunohistochemistry (IHC) using the D5F3 clone (1 in 200 dilution) on a Bond-III 
system (Leica, UK). Samples positive by ALK IHC were tested for ALK gene 
rearrangements by fluorescence in situ hybridisation (FISH) using the Vysis ALK 
Break Apart FISH Probe Kit (Abbott Molecular). Pearson’s chi-squared test and 
Fisher’s Exact test were used to explore associations between clinicopathological and 
molecular parameters. TTF1 IHC was performed, if not already carried out for 
histological diagnosis, on samples with EGFR mutations. TTF1 IHC was performed 
on a Bond-III using the 8G7G3/1 antibody (M3575, Dako) with 20 minutes retrieval 
and Leica solution ER2. Sections stained with TTF1 were assessed for the presence of 
any nuclear staining by a consultant histopathologist specialising in respiratory 
pathology.  
 
The number and diagnoses of all lung cancer patients registered in the Borders, 
Dumfries & Galloway, Fife and Lothian Health Boards between April 2013 and 
March 2014 were supplied by the South East Scotland Cancer Network (SCAN). 
These data, and the results of the clinical audit, were used to develop models of 
testing using four algorithms. 1. In the reflex model samples from all patients 
diagnosed with non-squamous NSCLC, regardless of intention to treat with EGFR or 
ALK targeted therapies, would be simultaneously tested for EGFR, KRAS and ALK 
mutations. 2. In the request model only samples from patients with metastatic or 
locally advanced (stage III and IV) non-squamous NSCLC, i.e. those eligible for 
treatment with EGFR TKIs or ALK inhibitors, would be simultaneously tested for 
EGFR, KRAS and ALK mutations. In addition, the number of patients initially 
diagnosed with stage I or II who would have progressed to stage III or IV was 
estimated from the clinical audit data and included in the model. 3. The serial testing 
model was designed to utilise the mutually exclusive relationship between EGFR, 
KRAS and ALK mutations in order to minimise testing. All patients eligible for testing 
in the request model would be tested for KRAS mutations; only those with no 
mutations would have EGFR mutation analysis and only samples with no KRAS or 
EGFR mutations would have ALK rearrangement analysis. 4. Finally, in the TTF1-
serial model all patients selected with the request model would be initially tested for 
TTF1 and ALK rearrangements; given the limited data available this model does not 
assume a correlation between TTF1 expression and ALK rearrangements. Only TTF1 
positive ALK negative samples would have KRAS mutation analysis and only those 
with no KRAS mutations would be tested for EGFR mutations. The cost of testing 
using each model was estimated using the CMD Impact Business Planning Tool 
developed by the Royal College of Pathologists, Cancer Research UK and the 
Association of the British Pharmaceutical Industry (https://www.rcpath.org/cmd-
impact.html). The estimated annual cost of each model was represented as a 
proportion of the cost of the request model. 
 
RESULTS 
Between January 2011 and March 2014 there were 710 requests for lung cancer 
molecular pathology testing; of those suitable for testing 10.5% had EGFR mutations, 
36.5% had KRAS mutations, 2.3% had ALK gene rearrangements, and 79.4% showed 
positive staining for TTF1. No samples were found to have co-occurring EGFR, 
KRAS or ALK mutations. Although positive TTF1 IHC was not predictive for the 
presence of EGFR mutations (positive predictive value 13.4%, n= 461) no samples 
with EGFR mutations were negative for TTF1expression. After additional TTF1 IHC 
117 specimens with EGFR mutations were positive for TTF1 nuclear staining and 1 
showed only cytoplasmic staining and was therefore considered negative; equating to 
a negative predictive value (NPV) of 99.05% 
Four hundred patients with histopathology/ cytopathological samples were diagnosed 
with adenocarcinoma or non-small cell lung carcinoma between April 2013 and 
March 2014; of those 370 were stage III or IV and therefore eligible for EGFR TKI or 
ALK inhibitor therapy. Based on these figures, the annual cost of lung cancer 
molecular pathology testing by the request model was estimated to be 92.5% of that of 
the reflex model. Testing by the serial model was estimated to cost only 67.3% of the 
request model. If TTF1 were fully validated as a negative predictive biomarker the 
cost of testing could be reduced to 62.5% of the reflex model (summarised in table 2).  
 
Table 2: Summary of models 
Model Cohort Tests carried out Cost relative 
to reflex 
model 
Reflex All non-squamous NSCLC EGFR, ALK & KRAS 
simultaneously 
100% 
Request 
Stage III or IV non-
squamous NSCLC 
92.5% 
Serial 
KRAS;  
KRAS neg > EGFR;  
KRAS & EGFR neg > ALK 
67.3% 
TTF1-
serial 
TTF1 & ALK;  
TTF1 pos & ALK neg > KRAS;  
TTF1 pos & KRAS neg > EGFR  
62.5% 
Neg= no mutation detected, Pos= positive expression of protein 
 
DISCUSSION 
In our cohort TTF1 IHC had a high negative predictive value (NPV) for EGFR 
mutations supporting the association previously reported in several studies with 
Caucasian populations,6 7 9 12 although this correlation seems to be weaker in East 
Asian populations.13 15-17 Two studies used a scoring system to determine TTF1 status 
which may have reduced the number of positive samples and therefore lowered the 
NPV.7 16 Our study was carried out in a clinical diagnostic setting and any nuclear 
staining, even focal staining, was considered positive for TTF1. One sample from a 
total of 118 EGFR mutation positive patients showed only cytoplasmic staining with 
the TTF1 antibody; upon further investigation this biopsy, which had a p.(Gly719X) 
EGFR mutation, was taken post chemo-radiation. A previous specimen taken pre-
treatment was TTF1 positive, however since several years had elapsed between the 
two samples it was not possible to determine if the latter biopsy was a recurrence or a 
second primary tumour. Unfortunately, there was too little tissue remaining in the pre-
treatment sample to perform EGFR mutation analysis.  
 
Many clinical laboratories are experiencing increasing pressures to reduce costs; 
where funding is restricted algorithms must supply the most cost effective use of 
limited resources without compromising clinical utility and the welfare of patients. 
The saving represented by only testing patients eligible for treatment with targeted 
therapies (the request model) would be easily achievable in most clinical laboratories 
without any detrimental effect on patient care; a proposal supported by data from 
another institution.18 In reality NHS Lothian employs a system between the reflex and 
request models and accepts requests from oncologists if a patient is being considered 
for treatment or from histopathologists if the diagnostic sample confirms distant 
metastatic disease. 
 
Currently there is no direct therapeutic impact of KRAS nevertheless KRAS mutation 
status in non-squamous NSCLC does have some value, since a large proportion of 
tumours carry mutations their detection ensures, particularly in samples with a low 
proportion of neoplastic cells, that the appropriate tissue has been tested. Withdrawing 
KRAS analysis would reduce costs by 18% compared to the reflex model. However, 
stratifying the cohort using the serial model, including KRAS analysis, would allow a 
much greater saving; a 32.7% reduction compared to the reflex model. Recent 
European Society for Medical Oncology (ESMO) guidelines do not recommend 
KRAS mutation analysis in a serial model due to the effect on turnaround times and 
the potential waste of tumour material.19 However KRAS mutation analysis can be 
performed in less than a day and in our lab is already frequently available before 
performing EGFR analysis. On average lung cancer molecular pathology testing in 
NHS Lothian is reported in 3.8 working days; the addition of an extra day for KRAS 
mutation analysis would have little impact on patient treatment and falls well within 
the 10 working days recommended by the joint guidelines from the College of 
American Pathologists, International Association for the Study of Lung Cancer, and 
Association for Molecular Pathology.1 Where specimen size, and therefore DNA 
yield, is limiting samples should proceed straight to EGFR analysis to avoid the risk 
of exhausting the sample. Laboratories whose primary method is a multiplex assay, 
for example next generation sequencing (NGS), would not benefit from the serial 
model; but for many labs NGS is not an option and will, for the foreseeable future, 
continue to carry out single genes analyses.  
 
The value of TTF1 IHC may not be limited to cost efficiency, if an initial specimen 
was considered insufficient for molecular analysis the TTF1 status may help 
determine the value of subjecting a patient to a procedure to obtain a repeat sample. 
Although promising there is, as yet, too little data on the association between TTF1 
IHC and EGFR to fully support its use as a negative predictor for EGFR mutations. 
Further audits by molecular pathology laboratories could elucidate this relationship 
and help confirm or refute the use of this readily available histopathology biomarker 
as a screening tool prior to EGFR mutation analysis. 
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